Cancer Treatment Developer Cellectis Fine-Tunes $130M IPO
Cellectis SA set terms Tuesday to raise nearly $130 million in its U.S. initial public offering, as the French company prepares to launch a dual listing on the Nasdaq alongside the...To view the full article, register now.
Already a subscriber? Click here to view full article